The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
Abstract
Purpose: The aim of this subset analysis was to determine if bortezomib treatment is associated with increased incidence of varicella-zoster virus (VZV) reactivation in patients with relapsed multiple myeloma (MM). Patients and Methods: Incidence of herpes zoster was evaluated in 663 patients with relapsed MM from the phase III APEX trial comparing single-agent bortezomib with high-dose dexamethasone. Results: Bortezomib was associated with a significantly higher incidence of herpes zoster compared with dexamethasone treatment (13%, 42 of 331 v 5%, 15 of 332; P = .0002). Most herpes zoster infections were grade 1/2; incidences of grade 3/4 events (1.8% v 1.5%) and infections considered serious adverse events (1.5% v 0.9%) were similar between treatment arms, and no herpes zoster–related deaths occurred. Neither the time to onset of the herpes event nor the patients’ absolute lymphocyte counts at baseline differed significantly between arms. VZV reactivation was the only herpes viral event noted to be significantly elevated in the bortezomib treatment group compared with the dexamethasone treatment group (P = .0002). The incidence of non–VZV-related herpes viral infections was comparable between arms. No additional risk factors for herpes zoster reactivation were identified. Conclusion: Further studies are needed to explain these observations and their implications; however, for patients treated with bortezomib or bortezomib-containing regimens, the risk of VZV reactivation should be monitored and routine use of antiviral prophylaxis considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationHideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationA phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Self-citationGlucocorticoids and invasive fungal infections
Lionakis, M. S., & Kontoyiannis, D. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14904-5 · Cited by 669
Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2007) · Blood · doi:10.1182/blood-2006-08-036947 · Cited by 513
Self-citationMa, M. H., Yang, H. H., Parker, K., Manyak, S. J., Friedman, J. M., Altamirano, C. V., Wu, Z.-Q., Borad, M. J., Frantzen, M., Roussos, E., et al. (2003) · PubMed · Cited by 414
Mateos, M.-V., Hernández, J.-M., Hernández, M.-T., Gutiérrez, N.-C., Palomera, L., Fuertes, M., Díaz-Mediavilla, J., Lahuerta, J.-J., de la Rubia, J., Terol, M.-J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-019778 · Cited by 389
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292
Self-citationSun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401563101 · Cited by 244
Blanco, B., Pérez-Simón, J. A., Sánchez-Abarca, L. I., Carvajal-Vergara, X., Mateos, J., Vidriales, B., López-Holgado, N., Maiso, P., Alberca, M., Villarón, E., et al. (2006) · Blood · doi:10.1182/blood-2005-05-2118 · Cited by 193
Preventing Varicella-Zoster Disease
Hambleton, S., & Gershon, A. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.70-80.2005 · Cited by 153
Schütt, P., Brandhorst, D., Stellberg, W., Poser, M., Ebeling, P. R., Müller, S., Buttkereit, U., Opalka, B., Lindemann, M., Grosse‐Wilde, H., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500472503 · Cited by 138
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Nencioni, A., von Schwarzenberg, K., Brauer, K. M., Schmidt, S. M., Ballestrero, A., Grünebach, F., & Brossart, P. (2006) · Blood · doi:10.1182/blood-2005-08-3494 · Cited by 135
Clinical and Molecular Pathogenesis of Varicella Virus Infection
Gilden, D. H., Cohrs, R. J., & Mahalingam, R. (2003) · Viral Immunology · doi:10.1089/088282403322396073 · Cited by 88
Millennium Pharmaceuticals, Inc.
(2004) · Personalized Medicine · doi:10.1517/17410541.1.1.131 · Cited by 75
Thalidomide as an anti‐cancer agent
Kumar, S. K., Witzig, T. E., & Rajkumar, S. V. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00184.x · Cited by 72
Proteasome inhibitor‐induced apoptosis in human monocyte‐derived dendritic cells
Nencioni, A., Garuti, A., von Schwarzenberg, K., Cirmena, G., Bello, M. G. D., Rocco, I., Barbieri, E., Brossart, P., Patrone, F., & Ballestrero, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535298 · Cited by 71
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients
Tong, Y., Qian, J. J., Li, Y., Meng, H. T., & Jin, J. (2006) · American Journal of Hematology · doi:10.1002/ajh.20838 · Cited by 44
Kl, W., van Wieringen, W. N., Vellenga, E., Zweegman, S., Lokhorst, H. M., & Sonneveld, P. (2005) · PubMed · Cited by 32
Self-citationUy, G. L., Peles, S., Fisher, N. M., Tomasson, M. H., DiPersio, J. F., & Vij, R. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.11.355 · Cited by 13
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Röllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C., Holmberg, E., Mellqvist, U.-H., Landgren, O., Bjorkholm, M., Hultcrantz, M., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2015) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 524
Flowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., Kuderer, N. M., Langston, A. A., Marr, K. A., Rolston, K. V. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8661 · Cited by 448
Metadata
- Authors
- Chanan-Khan, A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Neuwirth, R., Anderson, K. C., & Richardson, P. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-10
- Volume
- 26
- Issue
- 29
- Pages
- 4784-4790
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159195400
- Cited by
- 263
- References
- 21
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.